Paper31035320
Cholesterol Trafficking: An Emerging Therapeutic Target for Angiogenesis and Cancer.
Lyu J and 2 others. Cells, 2019. Cited by 53 papers, by iCite.
Cite this record
ConductScience Library. Cholesterol Trafficking: An Emerging Therapeutic Target for Angiogenesis and Cancer. Papers, record 31035320. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/31035320
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Angiogenesis Inhibitors | Major topic |
| Cholesterol | Major topic |
| Endothelial Cells | Major topic |
| Neoplasms | Major topic |
| Neovascularization, Pathologic | Major topic |
| Animals | |
| Biological Transport | |
| Cell Membrane | |
| Humans | |
| Signal Transduction |
Source PubMed
References58
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28747628 | The anti-cancer effects of itraconazole in epithelial ovarian cancer. | Sci Rep | 2017 | https://conductscience.org/library/papers/28747628 | PubMed |
| 2 | 15928087 | The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). | Proc Natl Acad Sci U S A | 2005 | https://conductscience.org/library/papers/15928087 | PubMed |
| 3 | 5319508 | The biological synthesis of cholesterol. | Science | 1965 | https://conductscience.org/library/papers/5319508 | PubMed |
| 4 | 24493717 | Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma. | J Clin Oncol | 2014 | https://conductscience.org/library/papers/24493717 | PubMed |
| 5 | 9150246 | Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types. | Biochim Biophys Acta | 1997 | https://conductscience.org/library/papers/9150246 | PubMed |
| 6 | 30123067 | Astemizole Inhibits mTOR Signaling and Angiogenesis by Blocking Cholesterol Trafficking. | Int J Biol Sci | 2018 | https://conductscience.org/library/papers/30123067 | PubMed |
| 7 | 10712926 | Cholesterol in signal transduction. | Curr Opin Cell Biol | 2000 | https://conductscience.org/library/papers/10712926 | PubMed |
| 8 | 28103683 | Simultaneous Targeting of NPC1 and VDAC1 by Itraconazole Leads to Synergistic Inhibition of mTOR Signaling and Angiogenesis. | ACS Chem Biol | 2017 | https://conductscience.org/library/papers/28103683 | PubMed |
| 9 | 26801248 | Divergence of Antiangiogenic Activity and Hepatotoxicity of Different Stereoisomers of Itraconazole. | Clin Cancer Res | 2016 | https://conductscience.org/library/papers/26801248 | PubMed |
| 10 | 6316883 | Low density lipoprotein metabolism by endothelial cells from human umbilical cord arteries and veins. | Arteriosclerosis | 1983 | https://conductscience.org/library/papers/6316883 | PubMed |
| 11 | 11106254 | Tamoxifen inhibits angiogenesis in estrogen receptor-negative animal models. | Clin Cancer Res | 2000 | https://conductscience.org/library/papers/11106254 | PubMed |
| 12 | 22723445 | Liver X receptor activation reduces angiogenesis by impairing lipid raft localization and signaling of vascular endothelial growth factor receptor-2. | Arterioscler Thromb Vasc Biol | 2012 | https://conductscience.org/library/papers/22723445 | PubMed |
| 13 | 23719382 | Control of angiogenesis by AIBP-mediated cholesterol efflux. | Nature | 2013 | https://conductscience.org/library/papers/23719382 | PubMed |
| 14 | 23546045 | Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer. | J Thorac Oncol | 2013 | https://conductscience.org/library/papers/23546045 | PubMed |
| 15 | 18216769 | Cellular cholesterol trafficking and compartmentalization. | Nat Rev Mol Cell Biol | 2008 | https://conductscience.org/library/papers/18216769 | PubMed |
| 16 | 21896639 | Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer. | Cancer Res | 2011 | https://conductscience.org/library/papers/21896639 | PubMed |
| 17 | 18235027 | Restoration of lysosomal pH in RPE cells from cultured human and ABCA4(-/-) mice: pharmacologic approaches and functional recovery. | Invest Ophthalmol Vis Sci | 2008 | https://conductscience.org/library/papers/18235027 | PubMed |
| 18 | 3476792 | Potentiation of antitumor activity of vincristine by the biscoclaurine alkaloid cepharanthine. | J Natl Cancer Inst | 1987 | https://conductscience.org/library/papers/3476792 | PubMed |
| 19 | 26646182 | Identification of NPC1 as the target of U18666A, an inhibitor of lysosomal cholesterol export and Ebola infection. | Elife | 2015 | https://conductscience.org/library/papers/26646182 | PubMed |
| 20 | 25465296 | Lipid rafts as major platforms for signaling regulation in cancer. | Adv Biol Regul | 2015 | https://conductscience.org/library/papers/25465296 | PubMed |
Cited by33
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 53 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41681900 | Targeting Pathways Implicated in Cholesterol Metabolism for Novel Cancer Therapy. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/41681900 | PubMed |
| 41055055 | The Contribution of Cholesterol and Squalene Synthase in Cancer: Molecular Mechanisms, Lipid Rafts and Therapeutic Approaches. | Med Res Rev | 2026 | https://conductscience.org/library/papers/41055055 | PubMed |
| 40739632 | Intracellular cholesterol: new functions and therapeutic approaches in NSCLC EGFR-TKI resistance. | Lipids Health Dis | 2025 | https://conductscience.org/library/papers/40739632 | PubMed |
| 40193204 | Roles of circadian clocks in macrophage metabolism: implications in inflammation and metabolism of lipids, glucose, and amino acids. | Am J Physiol Endocrinol Metab | 2025 | https://conductscience.org/library/papers/40193204 | PubMed |
| 39804138 | Ternary Complex Components Responsible for Rapid LDL Internalization as Biomarkers for Breast Cancer Associated with Proliferation and Early Recurrence. | Cancer Res Commun | 2025 | https://conductscience.org/library/papers/39804138 | PubMed |
| 39794417 | Epigenetic drug screening identifies enzyme inhibitors A-196 and TMP-269 as novel regulators of sprouting angiogenesis. | Sci Rep | 2025 | https://conductscience.org/library/papers/39794417 | PubMed |
| 39695567 | Functional omics of ORP7 in primary endothelial cells. | BMC Biol | 2024 | https://conductscience.org/library/papers/39695567 | PubMed |
| 39624425 | Exogenous estrogen partially rescues progesterone deficiency and autophagosome enlargement in Mcoln1 -/- mouse model with lysosomal storage disorder. | Reprod Dev Med | 2024 | https://conductscience.org/library/papers/39624425 | PubMed |
| 39243069 | Why make it if you can take it: review on extracellular cholesterol uptake and its importance in breast and ovarian cancers. | J Exp Clin Cancer Res | 2024 | https://conductscience.org/library/papers/39243069 | PubMed |
| 38285066 | Molecular signatures of angiogenesis inhibitors: a single-embryo untargeted metabolomics approach in zebrafish. | Arch Toxicol | 2024 | https://conductscience.org/library/papers/38285066 | PubMed |
| 38275613 | The Causal Relationship between PCSK9 Inhibitors and Malignant Tumors: A Mendelian Randomization Study Based on Drug Targeting. | Genes (Basel) | 2024 | https://conductscience.org/library/papers/38275613 | PubMed |
| 38136141 | Niemann-Pick Disease Type C (NPDC) by Mutation of NPC1 and NPC2: Aberrant Lysosomal Cholesterol Trafficking and Oxidative Stress. | Antioxidants (Basel) | 2023 | https://conductscience.org/library/papers/38136141 | PubMed |
| 37077571 | Machine learning-based prediction of cerebral hemorrhage in patients with hemodialysis: A multicenter, retrospective study. | Front Neurol | 2023 | https://conductscience.org/library/papers/37077571 | PubMed |
| 36632458 | M6PR- and EphB4-Rich Exosomes Secreted by Serglycin-Overexpressing Esophageal Cancer Cells Promote Cancer Progression. | Int J Biol Sci | 2023 | https://conductscience.org/library/papers/36632458 | PubMed |
| 36344536 | A multi-marker integrative analysis reveals benefits and risks of bariatric surgery. | Sci Rep | 2022 | https://conductscience.org/library/papers/36344536 | PubMed |
| 35956750 | GPR183 Regulates 7α,25-Dihydroxycholesterol-Induced Oxiapoptophagy in L929 Mouse Fibroblast Cell. | Molecules | 2022 | https://conductscience.org/library/papers/35956750 | PubMed |
| 35924044 | Ezetimibe and Cancer: Is There a Connection? | Front Pharmacol | 2022 | https://conductscience.org/library/papers/35924044 | PubMed |
| 35864437 | Cholesterol homeostasis and cancer: a new perspective on the low-density lipoprotein receptor. | Cell Oncol (Dordr) | 2022 | https://conductscience.org/library/papers/35864437 | PubMed |
| 35289033 | Tumor endothelial cell-induced CD8+ T-cell exhaustion via GPNMB in hepatocellular carcinoma. | Cancer Sci | 2022 | https://conductscience.org/library/papers/35289033 | PubMed |
| 35251975 | Involvement of LDL and ox-LDL in Cancer Development and Its Therapeutical Potential. | Front Oncol | 2022 | https://conductscience.org/library/papers/35251975 | PubMed |
Genes19
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/31035320
GET https://conductscience.org/api/papers/v1/31035320/references?page=2